Shanghai MOYOM Biotechnology Funding Round

9/28/2026

Venture Equity

Unknown

Undisclosed

The company intends to use the funds to to accelerate clinical translation, pursue additional regulatory approvals and expand into overseas markets, while continuing to invest in next-generation regenerative biomaterials.

Private & Independent

Biopharmaceutical

Building 7, No. 999 Jiangyue Road, Minhang District
Shanghai, 201114
China

Shanghai MOYOM Biotechnology Co., Ltd., located in Shanghai, the economic center of China, is dedicated to the research, development, production, sales, and consulting services of nano to micro biomedical materials and absorbable Class III implantable products. The company has secured strategic investments from Shanghai STVC Group under the control of the Shanghai State-owned Assets Supervision and Administration Commission, Hengxu Capital under the control of SAIC, Jinding Capital and Boyuan Capital.Since 2000, the core R&D team has highlighted the research and development of medical calcium phosphates, calcium silicates, polylactic acids, polyamino acids, polycaprolactone, recombinant human collagen, and bone morphogenetic proteins (rhBMPs). With professional expertise and strong research capabilities, MOYOM has been driving innovation in biomedical materials.